About Beckman Coulter Diagnostics

Beckman Coulter Diagnostics advances neurodegenerative disease research through high-quality blood-based biomarker assays, scalable automated immunoassay platforms, and collaboration with leading researchers. Our Neuro ACCESS Biomarker Collection is designed to support research needs from early translation through large-scale biomarker studies and future test commercialization.

With more than 90 years of diagnostics development experience, Beckman Coulter brings rigorous process control, analytical sensitivity, reproducibility, and workflow expertise to Research Use Only assay development.

Beckman Coulter is a part of Danaher, a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve their most complex scientific and clinical challenges, helping move innovations from discovery to delivery faster for patients who depend on them.

Empowering Neurodegenerative Disease Research

Explore an expanding portfolio of automated blood-based biomarker assays supporting research into amyloid pathology, tau pathology, neurodegeneration, co-pathologies, and genetic risk stratification.

Access p-Tau217 – Research into amyloid and tau pathology.

Access BD-Tau – Research into brain-derived tau and neurodegeneration.

Access BD-pTau217 – High-specificity detection of brain-derived pTau217 for Alzheimer’s disease research, including staging and characterization of research populations.

Access GFAP – Research into glial activation and neurodegenerative disease biology.

Access NfL – Research into neuroaxonal injury across neurodegenerative disease studies.

Access APOE ε4 – Proteotypic research assay supporting investigation of APOE ε4 zygosity status.

Access β-Amyloid 1-42 – Research into amyloid pathology.